Liang Xiao

This inventor holds 12 USPTO granted patents and 12 published patent applications, plus 4 CIPO patents and 3 EPO patents. Top assignees: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Klus Pharma Inc., Ampsource Biopharma Shanghai Inc.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Liang Xiao. Retrieved from https://idiyas.com/inventor/liang-xiao-bqfvhe1b

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 12)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 9)

EPO Patents = 3 (Patent Applications = 15)

Average Co-Inventor Count = 9.4

ph-index = 1

Forward Citations = 1(Granted Patents)

Location History:

Sichuan, CN (2019 - 2024)
Chengdu, CN (2021 - 2024)

Company Filing History:

10 out of 26

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Ampsource Biopharma Shanghai Inc.

patents

4. 1 out of 3

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2019-2026

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12753230 - ANTI-NECTIN-4 ANTIBODY, CONJUGATE INCLUDING THE SAME, AND APPLICATION THEREOF (2026-10-06),

2. 12297265 - Antibody and use thereof (2025-05-13),

3. 12258419 - Anti-FXI/FXIa antibody and use thereof (2025-03-25),

4. 12150944 - Use of anti-HER2 antibody-drug conjugate in cancer treatment (2024-11-26),

5. 11970506 - Bioactive molecule conjugate, preparation method and use thereof (2024-04-30),

6. 11903948 - Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof (2024-02-20),

7. 11884725 - Antibody against TIM-3 and application thereof (2024-01-30),

8. 11655295 - Anti-LAG-3 antibody and use thereof (2023-05-23),

9. 11421029 - Recombinant bispecific antibodies to PD-L1 and CTLA-4 (2022-08-23),

10. 11207420 - Cytotoxin and conjugate, uses of same and preparation method therefor (2021-12-28),

11. 11136413 - PDL-1 antibody, pharmaceutical composition thereof, and uses thereof (2021-10-05),

12. 10465014 - PDL-1 antibody, pharmaceutical composition thereof, and uses thereof (2019-11-05),

Title: Innovations and Contributions of Inventor Liang Xiao

Introduction

Liang Xiao is a prominent inventor based in Sichuan, China, known for his significant contributions to the field of biopharmaceuticals. With a total of 11 patents to his name, he has made remarkable advancements in therapeutic monoclonal antibodies.

Latest Patents

One of his latest patents is titled "Antibody and use thereof." This invention provides an anti-CLDN18.2 antibody or an antigen-binding fragment, along with nucleic acid molecules for encoding the antibody and fragment. The anti-CLDN18.2 antibody exhibits high specificity and affinity to CLDN18.2, effectively binding to it and mediating the killing of CLDN18.2 expressing cells. Additionally, this patent includes a pharmaceutical composition comprising the antibody or fragment, which can be utilized in the preparation of drugs for the prevention and treatment of tumors. Another significant patent is the "Anti-FXI/FXIa antibody and use thereof." This invention relates to therapeutic monoclonal antibodies and provides an anti-FXI/FXIa antibody or an antigen-binding fragment, along with nucleic acid molecules encoding the same. The anti-FXI/FXIa antibody demonstrates specificity and high affinity to FXI/FXIa, effectively inhibiting its activity. This patent also includes a pharmaceutical composition for the prevention and treatment of diseases related to coagulation or thromboembolism.

Career Highlights

Liang Xiao has worked with notable companies such as Sichuan Kelun Biotech Biopharmaceutical Co., Ltd. and Klus Pharma Inc. His work in these organizations has contributed to the development of innovative biopharmaceutical solutions.

Collaborations

Liang has collaborated with talented individuals in his field, including Tongtong Xue and Jingyi Wang. These collaborations have further enhanced his research and development efforts.

Conclusion

Liang Xiao's innovative work in the field of biopharmaceuticals, particularly in the development of therapeutic antibodies, showcases his significant contributions to medical science. His patents reflect a commitment to advancing healthcare solutions and improving treatment options for various diseases.

Profile summary based on public USPTO records.